Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADX-914 · 2 trials · 2 indications
Severity score is based on evaluation of severity of atopic dermatitis in 4 body regions (head and neck, trunk, upper limbs, and lower limbs). The minimum score is 0 (less severe) and maximum score is 72 (most severe).
Listing and summary of AE incidence
Listing of clinically significant changes in PE findings
Listing and change from baseline to end of study
Listing and change from baseline to end of study
Listing and change from baseline to end of study
Change in 12-lead ECG parameters from baseline to end of study
| Arm | Type | Description |
|---|---|---|
| ADX-914 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Experimental: Cohort 1:1 - 1:6 ADX-914 | EXPERIMENTAL | ADX-914 single SC dose |
| Placebo Comparator: Cohort 1:1 - 1:6 placebo | PLACEBO_COMPARATOR | Placebo single SC dose |
| Experimental: Cohort 2:1- 2:3 | EXPERIMENTAL | ADX-914 multiple SC dose once every 2 weeks for 6 weeks |
| Placebo Comparator: Cohort 2:1- 2:3 | PLACEBO_COMPARATOR | Placebo multiple SC dose once every 2 weeks for 6 weeks |
| Name | Type | Description |
|---|---|---|
| ADX-914 | DRUG | Subcutaneous administration of ADX-914 |
| Placebo | DRUG | Subcutaneous administration of Placebo |
Inclusion Criteria: 1. Age ≥18 years, inclusive, at time of informed consent, with chronic AD (duration of disease ≥3 years) diagnosed by the Eichenfield revised criteria of Hanifin and Rajka. 2. Moderate to severe disease activity at baseline and screening defined as: 1. BSA affected ≥10% 2...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | 611 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
ADX-914 is an investigational small molecule being studied for the treatment of moderate to severe atopic dermatitis. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities. The drug targets IL-7Rα, a protein involved in immune signaling.
ADX-914 targets IL-7Rα, a protein receptor involved in immune cell signaling. By modulating this target, the drug aims to address inflammatory pathways relevant to atopic dermatitis. This mechanism is being evaluated in clinical trials for safety and efficacy.
ADX-914 is being developed by Q32 Bio Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in atopic dermatitis. Q32 Bio Inc. is publicly traded under the ticker QTTB.
ADX-914 is in Phase 2 clinical development for atopic dermatitis. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies. The Phase 2 trial is actively not recruiting participants, and earlier Phase 1 studies have been completed.
ADX-914 has been studied in two clinical trials. A Phase 1 trial (NCT04485481) evaluated single and multiple ascending doses in healthy volunteers and has been completed. A Phase 2 trial (NCT05509023), called SIGNAL-AD, is evaluating safety and efficacy in patients with moderate to severe atopic dermatitis and is active but not recruiting.
ADX-914 is the primary name for this investigational drug. No alternative names have been reported in clinical trial registrations. It is a small molecule targeting IL-7Rα, developed by Q32 Bio Inc., and is being studied for atopic dermatitis.